Up to 70% of ovarian cancer patients are diagnosed with advanced-stage disease and the degree of cytoreduction is an important survival prognostic factor. The aim of this study was to evaluate if Raman spectroscopy could detect cancer from different organs within the abdominopelvic region, including the ovaries. A Raman spectroscopy probe was used to interrogate specimens from a cohort of 9 patients undergoing cytoreductive surgery, including 4 ovarian cancer patients and 3 patients with endometrial cancer. A feature-selection algorithm was developed to determine which spectral bands contributed to cancer detection and a machine-learning model was trained. The model could detect cancer using only 8 spectral bands. The receiver-operating-characteristic (ROC) curve had an area-under-the-curve (AUC) of 0.96, corresponding to an accuracy, a sensitivity and a specificity of 90%, 93% and 88%, respectively. These results provide evidence multispectral Raman spectroscopy could be developed to detect ovarian cancer intraoperatively. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.
About The Expert
Sandryne David
- Department of Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada.
- Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
Arthur Plante
- Department of Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada.
- Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
Frédérick Dallaire
- Department of Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada.
- Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
Jean-Philippe Tremblay
- Department of Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada.
Guillaume Sheehy
- Department of Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada.
- Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
Elizabeth Macdonald
- Cancer Therapeutics Program, Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada.
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Laura Forrest
- Cancer Therapeutics Program, Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada.
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Manijeh Daneshmand
- Cancer Therapeutics Program, Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada.
- Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Dominique Trudel
- Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
Brian C Wilson
- Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.
Laura Hopkins
- Department of Obstetrics and Gynecology, University of Ottawa and The Ottawa Hospital, Ottawa, Ontario, Canada.
Sangeeta Murugkar
- Department of Physics, Carlton University, Ottawa, Canada.
Barbara Vanderhyden
- Cancer Therapeutics Program, Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada.
- Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Frédéric Leblond
- Department of Engineering Physics, Polytechnique Montreal, Montreal, Quebec, Canada.
- Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
References
PubMed